Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Xtant Medical HoldingsXTNT -2.24%22 Equity-to-Asset is 0.50 as of Jun. 2026, which is 9% above its 10-year median of 0.46. GuruFocus rates XTNT with a GF Score™ of 22/100 and a GF Value™ of $0.53 (Possible Value Trap). The stock has 2 warning signs investors should review. Among 853 Medical Devices & Instruments companies, Xtant Medical Holdings ranks worse than 66.82% on this metric.
Xtant Medical Holdings (AMEX:XTNT) Equity-to-Asset Explanation
Equity to Asset ratio can vary greatly across different industries, as they have different capital structure. A company with smaller Equity to Asset ratio (more leveraged) may have higher ROE % because of the leverage.
For banks, the required minimum Equity to Asset ratio by regulation is 5%. Some stronger banks may have Equity to Asset Ratio of more than 10%.
Xtant Medical Holdings Equity-to-Asset Related Terms
Xtant Medical Holdings Equity-to-Asset Historical Data
* Premium members only.
The historical data trend for Xtant Medical Holdings's Equity-to-Asset can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
XTNT vs NNOX, POSC, MDAI: Equity-to-Asset Comparison
For the Medical Devices subindustry, Xtant Medical Holdings's Equity-to-Asset, along with its competitors' market caps and Equity-to-Asset data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Xtant Medical Holdings Equity-to-Asset vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Xtant Medical Holdings's Equity-to-Asset distribution charts can be found below:
* The bar in red indicates where Xtant Medical Holdings's Equity-to-Asset falls into.
Xtant Medical Holdings Equity-to-Asset Calculation
Equity to Asset ratio measures the ratios of the portion of the asset owned by shareholders out of the total asset. It indicates the leverage of the company, and the amount of debt the company uses in its operation.
Equity to Asset ratio is calculated by dividing total stockholders equity by total asset.
Xtant Medical Holdings's Equity to Asset Ratio for the fiscal year that ended in Dec. 2025 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Xtant Medical Holdings (XTNT) has a Equity-to-Asset of 0.50 as of Jun. 2026. Equity-to-asset ratio equals total company equity divided by total assets. It measures financial leverage. View historical data on Xtant Medical Holdings and its competitors. This is near median its historical median of 0.46. According to the industry distribution chart, Xtant Medical Holdings ranks #570 out of 853 companies in the Medical Devices & Instruments industry, placing it in the top 66.8%.
Is Xtant Medical Holdings' Equity-to-Asset too high?
Xtant Medical Holdings' current Equity-to-Asset of 0.50 is near median its 10-year median of 0.46. The Medical Devices & Instruments industry median Equity-to-Asset is 0.64. Xtant Medical Holdings' value of 0.50 is 21.9% below this industry median. Based on the distribution chart, Xtant Medical Holdings ranks #570 out of 853 companies in the Medical Devices & Instruments industry, which is below the industry midpoint. Overall, Xtant Medical Holdings has a GF Score™ of 22/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Xtant Medical Holdings' Equity-to-Asset compare to NNOX and POSC?
According to the Medical Devices & Instruments industry distribution chart, Xtant Medical Holdings ranks #570 out of 853 companies for Equity-to-Asset. This places Xtant Medical Holdings in the lower half of its industry. The industry median Equity-to-Asset is 0.64. Xtant Medical Holdings' value of 0.50 is 21.9% below this benchmark. While the company's 10-year median is 0.46 vs. the industry median of 0.64, Xtant Medical Holdings has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Equity-to-Asset for a Medical Devices & Instruments company?
The median Equity-to-Asset among Medical Devices & Instruments companies is 0.64, based on 853 companies in the industry. Companies in the top quartile (top 25%) have a Equity-to-Asset significantly above this median, while those in the bottom quartile fall well below. However, Equity-to-Asset should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Xtant Medical Holdings's current Equity-to-Asset of 0.50 is 21.9% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Equity-to-Asset mean?
A high Equity-to-Asset can signal that a stock is expensive relative to its fundamentals. Equity-to-asset ratio equals total company equity divided by total assets. It measures financial leverage. View historical data on Xtant Medical Holdings and its competitors. For the Medical Devices & Instruments industry, the median Equity-to-Asset is 0.64 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Xtant Medical Holdings's current Equity-to-Asset is 0.50, which is near median its own 10-year median of 0.46. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Xtant Medical Holdings stock overvalued right now?
Based on GuruFocus' analysis, Xtant Medical Holdings (XTNT) is currently considered Possible Value Trap. The stock's GF Value™ is $0.53, compared to a current price of $0.31 — trading 42.5% below its estimated fair value. The current Equity-to-Asset is 0.50, which is near median its 10-year median of 0.46 and 21.9% below the Medical Devices & Instruments industry median of 0.64. Xtant Medical Holdings' overall GF Score™ is 22/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Equity-to-Asset calculated?
Equity-to-Asset is calculated from a company's financial statements. For Xtant Medical Holdings (XTNT), the current Equity-to-Asset is 0.50 as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Xtant Medical Holdings (XTNT) Overvalued in 2026?
Based on GuruFocus' analysis, Xtant Medical Holdings stock appears to be undervalued.
The current stock price of $0.31 is trading 42.5% below its estimated GF Value™ of $0.53.
GuruFocus considers Xtant Medical Holdings to be Possible Value Trap.
Key valuation signals for XTNT:
Equity-to-Asset: 0.50 (near median its 10-year median of 0.46)
GF Value™: $0.53 vs. price of $0.31 (42.5% below fair value)
Industry Position: 21.9% below the Medical Devices & Instruments median (#570 of 853)
No single metric tells the full story. See the XTNT stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Xtant Medical Holdings Inc is a medical technology company focused on the design, development, and commercialization of a comprehensive portfolio of orthobiologics and spinal implant systems to facilitate spinal fusion in complex spine, deformity and degenerative procedures. Its products are used by orthopedic spine surgeons and neurosurgeons to treat a variety of spinal disorders in the cervical, thoracolumbar, and interbody spine. The company's biomaterial products include OsteoSponge, OsteoSponge SC, OsteoSelect Plus DBM putty, OsteoWrap, and the line of 3Demin products, as well as other allografts. It generates a majority of its revenue from the U.S.
22GF Score
Get the complete analysis for XTNT
Equity-to-Asset is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
XTNT has been successfully added to your 
